Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.52B
EBITDA Margin
5.15%
TTM Avg
0.72%
3Y Avg
-7.50%
5Y Avg
-11313.48%
Market Cap
$1.46B
EBITDA Margin
21.45%
TTM Avg
-50.92%
3Y Avg
-538.26%
5Y Avg
-378.46%
Market Cap
$1.45B
EBITDA Margin
3.56%
TTM Avg
3.76%
3Y Avg
3.79%
5Y Avg
3.46%
Market Cap
$1.43B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
EBITDA Margin
-10195.54%
TTM Avg
-87388.52%
3Y Avg
-48181.08%
5Y Avg
-32386.50%
Market Cap
$1.65B
EBITDA Margin
0.06%
TTM Avg
-4.29%
3Y Avg
-15.38%
5Y Avg
-22.40%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.51B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 5.15% | 0.72% | -7.50% | -11313.48% |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 21.45% | -50.92% | -538.26% | -378.46% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 3.56% | 3.76% | 3.79% | 3.46% |
| Certara, Inc. (CERT)vs › | $1.57B | 18.52% | 17.87% | 16.34% | 15.57% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | -10195.54% | -87388.52% | -48181.08% | -32386.50% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 0.06% | -4.29% | -15.38% | -22.40% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 19.54% | 15.33% | 15.07% | 12.91% |
Gross Margin
N/A
EBITDA Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
